Erlotinib
Erlotinib
Erlotinib (pronounced er-loh-TIN-ib) is a medication used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is a type of tyrosine kinase inhibitor, specifically targeting the epidermal growth factor receptor (EGFR).
Etymology
The name "Erlotinib" is derived from the company that first developed the drug, Genentech, a subsidiary of Roche. The "tinib" suffix is common among tyrosine kinase inhibitors.
Usage
Erlotinib is used primarily in the treatment of NSCLC and pancreatic cancer. It works by inhibiting the tyrosine kinase enzyme, which is involved in the growth and spread of cancer cells. Erlotinib is often used when other cancer treatments have not been effective.
Side Effects
Common side effects of erlotinib include rash, diarrhea, and loss of appetite. More serious side effects can include lung disease, liver disease, and severe allergic reactions.
Related Terms
- Tyrosine kinase inhibitor: A type of drug that blocks the action of enzymes known as tyrosine kinases, which can stimulate the growth of cancer cells.
- Epidermal growth factor receptor (EGFR): A protein found on the surface of some cells to which epidermal growth factor binds, causing the cells to divide.
- Non-small cell lung cancer (NSCLC): The most common type of lung cancer, making up about 85% to 90% of all cases.
- Pancreatic cancer: A disease in which malignant (cancer) cells form in the tissues of the pancreas.
External links
- Medical encyclopedia article on Erlotinib
- Wikipedia's article - Erlotinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski